JP2004512258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004512258A5 JP2004512258A5 JP2001569247A JP2001569247A JP2004512258A5 JP 2004512258 A5 JP2004512258 A5 JP 2004512258A5 JP 2001569247 A JP2001569247 A JP 2001569247A JP 2001569247 A JP2001569247 A JP 2001569247A JP 2004512258 A5 JP2004512258 A5 JP 2004512258A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cell
- multivalent ligand
- ligand
- sre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003446 ligand Substances 0.000 description 75
- 239000000203 mixture Substances 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 150000001720 carbohydrates Chemical group 0.000 description 8
- 239000002062 molecular scaffold Substances 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000000844 Cell Surface Receptors Human genes 0.000 description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000008512 biological response Effects 0.000 description 6
- 239000002975 chemoattractant Substances 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000000962 organic group Chemical group 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000035605 chemotaxis Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 244000045947 parasite Species 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000007152 ring opening metathesis polymerisation reaction Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 0 CCC(C)(CC(C)(CN)C1(C)C=C)*C1N Chemical compound CCC(C)(CC(C)(CN)C1(C)C=C)*C1N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000011412 Complement 3d Receptors Human genes 0.000 description 1
- 108010023729 Complement 3d Receptors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19101400P | 2000-03-21 | 2000-03-21 | |
| PCT/US2001/009174 WO2001071309A2 (en) | 2000-03-21 | 2001-03-21 | Methods and reagents for regulation of cellular responses in biological systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004512258A JP2004512258A (ja) | 2004-04-22 |
| JP2004512258A5 true JP2004512258A5 (enExample) | 2008-05-22 |
Family
ID=22703769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001569247A Withdrawn JP2004512258A (ja) | 2000-03-21 | 2001-03-21 | 生物系における細胞応答の調節のための方法および試薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20030125262A1 (enExample) |
| EP (1) | EP1334118A4 (enExample) |
| JP (1) | JP2004512258A (enExample) |
| AU (2) | AU8149901A (enExample) |
| CA (1) | CA2403669A1 (enExample) |
| WO (1) | WO2001071309A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8149901A (en) * | 2000-03-21 | 2001-10-03 | Wisconsin Alummi Res Foundatio | Methods and reagents for regulation of cellular responses in biological systems |
| US20040248801A1 (en) * | 2000-03-21 | 2004-12-09 | Kiessling Laura L. | Methods and reagents for regulation of cellular responses in biological systems |
| EP1625156B1 (en) * | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| AU2004238870B8 (en) * | 2003-05-12 | 2010-04-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| EP1626983B8 (en) * | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| KR20070108140A (ko) * | 2004-11-11 | 2007-11-08 | 아피맥스, 인크. | 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드 |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| GB0426822D0 (en) * | 2004-12-07 | 2005-01-12 | Precisense As | Sensor for detection of glucose |
| GB0426823D0 (en) * | 2004-12-07 | 2005-01-12 | Precisense As | Sensor for detection of glucose |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| JP4742339B2 (ja) * | 2005-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出 |
| WO2007131084A2 (en) | 2006-05-03 | 2007-11-15 | Wisconsin Alumni Research Foundation | Magnetic resonance imaging contrast agents synthesized using ring-opening metathesis polymerization |
| EP2139524A1 (en) * | 2007-03-23 | 2010-01-06 | The Governors of the University of Alberta | Multivalent heterobifunctional polymers and methods of their use |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| US20140350370A1 (en) * | 2013-04-08 | 2014-11-27 | The Texas A&M University System | Glucose sensing assay |
| WO2018200951A1 (en) * | 2017-04-28 | 2018-11-01 | Tran David T | Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| US4883851A (en) * | 1988-07-25 | 1989-11-28 | California Institute Of Technology | Ring opening metathesis polymerization of strained cyclic ethers |
| US5100972A (en) * | 1990-07-16 | 1992-03-31 | General Electric Company | Cycloalkene terminated polyarylene ether |
| US5641622A (en) * | 1990-09-13 | 1997-06-24 | Baxter International Inc. | Continuous centrifugation process for the separation of biological components from heterogeneous cell populations |
| EP0773948A4 (en) * | 1992-04-03 | 1998-09-02 | California Inst Of Techn | HIGHLY ACTIVE RUTHENIUM OR OSMIUM METAL CARBEN COMPLEXES FOR OLEFIN METHETHESE REACTIONS AND THEIR SYNTHESIS |
| US5312940A (en) * | 1992-04-03 | 1994-05-17 | California Institute Of Technology | Ruthenium and osmium metal carbene complexes for olefin metathesis polymerization |
| US5710298A (en) * | 1992-04-03 | 1998-01-20 | California Institute Of Technology | Method of preparing ruthenium and osmium carbene complexes |
| US5599912A (en) * | 1993-09-10 | 1997-02-04 | Coretech, Inc. | Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances |
| US5587442A (en) * | 1994-12-23 | 1996-12-24 | Kiessling; Laura L. | Polyglycomers |
| US5831108A (en) * | 1995-08-03 | 1998-11-03 | California Institute Of Technology | High metathesis activity ruthenium and osmium metal carbene complexes |
| US6060570A (en) * | 1996-08-12 | 2000-05-09 | Bp Amoco Corporation | Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction |
| US6080826A (en) * | 1997-01-06 | 2000-06-27 | California Institute Of Technology | Template-directed ring-closing metathesis and ring-opening metathesis polymerization of functionalized dienes |
| US5889128A (en) * | 1997-04-11 | 1999-03-30 | Massachusetts Institute Of Technology | Living olefin polymerization processes |
| DE19742980A1 (de) * | 1997-09-29 | 1999-04-01 | Espe Dental Ag | Dentalmassen auf der Basis von ROMP-Oligomeren oder -Polymeren |
| US6121236A (en) * | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
| US6437119B1 (en) * | 1998-05-07 | 2002-08-20 | William Lawrence Truett | Compounds formed from two or three antibiotics and their processes of preparation |
| US6280527B1 (en) * | 1998-06-12 | 2001-08-28 | International Business Machines Corporation | Aqueous quaternary ammonium hydroxide as a screening mask cleaner |
| US6271315B1 (en) * | 1999-06-17 | 2001-08-07 | Wisconsin Alumni Research Foundation | Methods for making multivalent arrays |
| US6291616B1 (en) * | 1999-06-17 | 2001-09-18 | Wisconsin Alumni Research Foundation | Methods and reagents for capping ruthenium or osmium carbene-catalyzed ROMP products |
| HUP9902217A3 (en) * | 1999-06-29 | 2002-07-29 | Szegoe Peter | Polycation based bioconjugates and process for producing thereof |
| GB9916235D0 (en) * | 1999-07-09 | 1999-09-15 | Univ Durham | Process for polymerisation of olefins and novel polymerisable olefins |
| US20040248801A1 (en) * | 2000-03-21 | 2004-12-09 | Kiessling Laura L. | Methods and reagents for regulation of cellular responses in biological systems |
| AU8149901A (en) * | 2000-03-21 | 2001-10-03 | Wisconsin Alummi Res Foundatio | Methods and reagents for regulation of cellular responses in biological systems |
| WO2007131084A2 (en) * | 2006-05-03 | 2007-11-15 | Wisconsin Alumni Research Foundation | Magnetic resonance imaging contrast agents synthesized using ring-opening metathesis polymerization |
-
2001
- 2001-03-21 AU AU8149901A patent/AU8149901A/xx active Pending
- 2001-03-21 AU AU2001281499A patent/AU2001281499B2/en not_active Ceased
- 2001-03-21 JP JP2001569247A patent/JP2004512258A/ja not_active Withdrawn
- 2001-03-21 EP EP01959934A patent/EP1334118A4/en not_active Ceased
- 2001-03-21 US US09/815,296 patent/US20030125262A1/en not_active Abandoned
- 2001-03-21 CA CA002403669A patent/CA2403669A1/en not_active Abandoned
- 2001-03-21 WO PCT/US2001/009174 patent/WO2001071309A2/en not_active Ceased
-
2007
- 2007-07-13 US US11/777,455 patent/US20070270351A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004512258A5 (enExample) | ||
| US7138105B2 (en) | Compositions for delivery of therapeutics and other materials, and methods of making and using the same | |
| ES3035837T3 (en) | Recombinant pmhc class ii molecules | |
| US5738846A (en) | Interferon polymer conjugates and process for preparing the same | |
| JP3583420B2 (ja) | 二特異的試薬を用いた標的免疫化 | |
| Ilk et al. | S-layer fusion proteins—construction principles and applications | |
| US7951614B2 (en) | Methods and compositions for the production of monoclonal antibodies | |
| JP2022113163A (ja) | 核酸キャリア及び治療上の使用方法 | |
| US6117982A (en) | Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators | |
| CA2451353A1 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
| JP2006523453A5 (enExample) | ||
| AU2007200363B2 (en) | Colloidal metal compositions and methods | |
| CN101952414A (zh) | 通过树突细胞脱唾液酸糖蛋白受体(dc-asgpr)结合抗原呈递细胞的活性剂 | |
| JP2004501631A5 (enExample) | ||
| JP2004510160A5 (enExample) | ||
| JP2003500010A5 (enExample) | ||
| AU2006210705A1 (en) | MHC oligomer and method of making the same | |
| CN101636411B (zh) | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 | |
| JP2006515744A5 (enExample) | ||
| US6106835A (en) | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators | |
| Lien et al. | Polymorphonuclear granulocytes enhance lipopolysaccharide‐induced soluble p75 tumor necrosis factor receptor release from mononuclear cells | |
| CN101880326B (zh) | 干扰素‑β复合物 | |
| JPS58222031A (ja) | 合成ワクチン | |
| MacAdam et al. | Anti-mucus polyclonal antibody production, purification and linkage to the surface of albumin microspheres | |
| CN1121725A (zh) | 携有抗-cd4单克隆抗体的免疫微粒及其预防和/或治疗因hiv病毒感染所引起的病原状态或者作为生物制剂的用途 |